Fisher Asset Management LLC Boosts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fisher Asset Management LLC raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 1,609.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 539,025 shares of the company’s stock after acquiring an additional 507,500 shares during the quarter. Fisher Asset Management LLC’s holdings in IDEAYA Biosciences were worth $19,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Federated Hermes Inc. lifted its position in shares of IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after acquiring an additional 500,046 shares in the last quarter. Vanguard Group Inc. boosted its stake in IDEAYA Biosciences by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,971,497 shares of the company’s stock worth $80,171,000 after purchasing an additional 141,844 shares during the period. Boone Capital Management LLC raised its position in shares of IDEAYA Biosciences by 15.0% during the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock valued at $15,397,000 after buying an additional 74,249 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of IDEAYA Biosciences by 199.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 437,356 shares of the company’s stock valued at $11,800,000 after buying an additional 291,240 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of IDEAYA Biosciences during the fourth quarter worth $12,328,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the transaction, the chief executive officer now owns 677,887 shares in the company, valued at approximately $30,870,973.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now directly owns 24,531 shares of the company’s stock, valued at approximately $1,128,916.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at $30,870,973.98. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

IDEAYA Biosciences Stock Up 1.7 %

Shares of IDEAYA Biosciences stock opened at $42.18 on Monday. The firm’s 50 day moving average price is $42.74 and its 200-day moving average price is $38.14. IDEAYA Biosciences, Inc. has a 52-week low of $18.50 and a 52-week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.05). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $8.84 million. The company’s revenue was down 3.0% on a year-over-year basis. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDYA has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. The Goldman Sachs Group upped their price objective on IDEAYA Biosciences from $36.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Capital One Financial reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada upped their price target on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $46.60.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.